BTIG analyst Jake Fuller maintained a Buy rating on Expedia (EXPE – Research Report) today and set a price target of $235.00. The company’s ...
BTIG analyst Jake Fuller raised the firm’s price target on Expedia (EXPE) to $235 from $200 and keeps a Buy rating on the shares. The company ...
BTIG downgraded General Dynamics Corporation (NYSE:GD)to Neutral given the ongoing regulatory hurdles and supply chain disruptions that could hamper growth in 2025.
BTIG Research decreased their Q1 2025 earnings estimates for shares of Meritage Homes in a report issued on Tuesday, February ...
On Wednesday, BTIG analysts stood firm on their positive stance towards GeneDx (NASDAQ:WGS), reiterating a Buy rating and a $95.00 price target for the company's stock. With analyst targets ...
On Wednesday, BTIG analyst Carl Reichardt Jr. maintained a Neutral rating on shares of NVR Inc . (NYSE:NVR), while slightly lowering earnings per share (EPS) estimates for the upcoming years.
HOPE Therapeuticsâ„¢, Inc. ("HOPE"), a medical and technology driven company, and a wholly-owned subsidiary of NRx ...
NEW YORK--(BUSINESS WIRE)--BTIG announced today that it will host its annual MedTech, Digital Health, Life Science and Diagnostic Tools Conference on Tuesday, February 11 through Wednesday ...
Oncocyte will host one-on-one meetings with interested investors. Investors attending the conference wishing to schedule a meeting are encouraged to contact BTIG to schedule.
Research analysts at BTIG Research reduced their Q4 2025 earnings estimates for shares of D.R. Horton in a research note issued to investors on Tuesday, January 28th. BTIG Research analyst C.
To schedule a one-on-one meeting, investors are encouraged to contact their BTIG representative. This press release includes forward-looking statements that involve risk and uncertainties.